ARDXArdelyx, Inc.
Price
-47%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market against it.
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ardelyx, Inc. (ARDX) reported revenue of $121M in Q2 2026 (quarter ended Jun 30, 2026), up 24% from the same quarter a year earlier. That came with a gross margin of 95% and net loss of $17M. For the full year FY2025, revenue was $407M (+22% year on year) and net income −$62M. Its largest product in Q2 2026 was Product IBSRELA at $86M, 70% of the disclosed total, well ahead of Product XPHOZAH at 26%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 17, 2026On August 11, 2026, Eric Foster notified Ardelyx, Inc. (the “Company”) of his decision to resign as Chief Commercial Officer of the Company, effective August 28, 2026.Other event · Form 8-K
- Aug 6, 2026Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 2, 2026On June 29, 2026, Ardelyx, Inc. (the “Company”) received $50.0 million of funding (the “Term F Loan”) pursuant to the loan and security agreement entered into in February 2022 by and between the Company and SLR Investment Corp., as collateral agent (the “Agent”) and the lenders listed in the agreement (collectively …New debt or off-balance-sheet obligation · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $123.6MThe company’s own SEC segment disclosure.
- Product IBSRELA$86.2M70%
- Product XPHOZAH$31.9M26%
- Product And Service Other$2.7M2%
- Product Supply$2.0M2%
- Non Cash Royalty Related To Sale Of Future Royalties$676.0K1%
- License$96.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.